|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1991-10-4
|
|
pubmed:abstractText |
Chimeric molecules comprising the A-chain of tissue-type plasminogen activator (t-PA) and the catalytic domain of urokinase-type plasminogen activator (u-PA) have intact enzymatic characteristics of u-PA, partial fibrin-binding properties of t-PA, and thrombolytic properties in animal models comparable with but not superior to those of single-chain u-PA (scu-PA). Deletion of the finger and growth factor domains (t-PA-delta FE/scu-PA-e) in such chimeras further reduces their affinity for fibrin.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0009-7322
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
84
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1216-34
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:1909220-Animals,
pubmed-meshheading:1909220-Blood Circulation,
pubmed-meshheading:1909220-Cricetinae,
pubmed-meshheading:1909220-Dogs,
pubmed-meshheading:1909220-Femoral Artery,
pubmed-meshheading:1909220-Fibrinolytic Agents,
pubmed-meshheading:1909220-Papio,
pubmed-meshheading:1909220-Pulmonary Embolism,
pubmed-meshheading:1909220-Rabbits,
pubmed-meshheading:1909220-Recombinant Proteins,
pubmed-meshheading:1909220-Structure-Activity Relationship,
pubmed-meshheading:1909220-Thrombolytic Therapy,
pubmed-meshheading:1909220-Thrombophlebitis,
pubmed-meshheading:1909220-Thrombosis,
pubmed-meshheading:1909220-Tissue Plasminogen Activator,
pubmed-meshheading:1909220-Urokinase-Type Plasminogen Activator
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
|
|
pubmed:affiliation |
Center for Thrombosis and Vascular Research, University of Leuven, Belgium.
|
|
pubmed:publicationType |
Journal Article
|
